The MALDI-TOF mass spectrometric view of the plasma proteome and peptidome

被引:277
作者
Hortin, Glen L. [1 ]
机构
[1] NIH, Dept Lab Med, Bethesda, MD 20892 USA
关键词
D O I
10.1373/clinchem.2006.069252
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: Matrix-assisted laser desorption/ionization time-of-flight mass,spectrometry (MALDI-TOF MS) and the related technique, surface-enhanced laser desorption/ionization (SELDI)-TOF MS, are being applied widely to analyze serum or plasma specimens for potential disease markers. Methods: Reports on the basic principles and applications of MALDI-TOF MS were reviewed and related to information on abundance and masses of major plasma proteins. Outcomes: MALDI-TOF MS is a particle-counting method that responds to molar abundance, and ranking of plasma proteins by molar abundance increases the rank of small proteins relative to traditional. ranking by mass abundance. Detectors for MALDI-TOF MS augment the bias for detecting smaller components by yielding stronger signals for an equivalent number of small vs large ions. Consequently, MALDI-TOF MS is a powerful tool for surveying small proteins and peptides comprising the, peptidome or fragmentome, opening this new,realm for analysis. It is complementary to techniques such as electrophoresis and HPLC, which have a bias for detecting larger molecules. Virtually all of the potential markers identified by MALDI-TOF MS to date represent forms of the most abundant plasma proteins. Conclusions: Analyses of serum or plasma by MALDI-TOF MS provide new information mainly about small proteins and peptides with high molar abundance. The spectrum of observed proteins and peptides suggests value for applications such as assessment of cardiovascular risk, nutritional status, liver injury, kidney failure, and systemic immune responses rather than early detection of cancer. Extending analysis by MALDI-TOF MS to lower abundance components, such as markers for early-stage cancers, probably will require more extensive specimen fractionation before analysis. (c) 2006 American Association for Clinical Chemistry.
引用
收藏
页码:1223 / 1237
页数:15
相关论文
共 130 条
  • [81] Overview of the HUPO Plasma Proteome Project: Results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly-available database
    Omenn, GS
    States, DJ
    Adamski, M
    Blackwell, TW
    Menon, R
    Hermjakob, H
    Apweiler, R
    Haab, BB
    Simpson, RJ
    Eddes, JS
    Kapp, EA
    Moritz, RL
    Chan, DW
    Rai, AJ
    Admon, A
    Aebersold, R
    Eng, J
    Hancock, WS
    Hefta, SA
    Meyer, H
    Paik, YK
    Yoo, JS
    Ping, PP
    Pounds, J
    Adkins, J
    Qian, XH
    Wang, R
    Wasinger, V
    Wu, CY
    Zhao, XH
    Zeng, R
    Archakov, A
    Tsugita, A
    Beer, I
    Pandey, A
    Pisano, M
    Andrews, P
    Tammen, H
    Speicher, DW
    Hanash, SM
    [J]. PROTEOMICS, 2005, 5 (13) : 3226 - 3245
  • [82] Identification of tyrosine sulfation in extracellular leucine-rich repeat proteins using mass spectrometry
    Önnerfjord, P
    Heathfield, TF
    Heinegård, D
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (01) : 26 - 33
  • [83] ORVISKY E, 2006, IN PRESS PROTEOMICS, V6
  • [84] Serum proteomic fingerprints of adult patients with severe acute respiratory syndrome
    Pang, RTK
    Poon, TCW
    Chan, KCA
    Lee, NLS
    Chiu, RWK
    Tong, YK
    Wong, RMY
    Chim, SSC
    Ngai, SM
    Sung, JJY
    Lo, YMD
    [J]. CLINICAL CHEMISTRY, 2006, 52 (03) : 421 - 429
  • [85] Alpha 1-microglobulin: clinical laboratory aspects and application
    Penders, J
    Delanghe, JR
    [J]. CLINICA CHIMICA ACTA, 2004, 346 (02) : 107 - 118
  • [86] PETERS T, 1983, PLASMA PROTEIN SECRE, P1
  • [87] Use of proteomic patterns in serum to identify ovarian cancer
    Petricoin, EF
    Ardekani, AM
    Hitt, BA
    Levine, PJ
    Fusaro, VA
    Steinberg, SM
    Mills, GB
    Simone, C
    Fishman, DA
    Kohn, EC
    Liotta, LA
    [J]. LANCET, 2002, 359 (9306) : 572 - 577
  • [88] Proteomics: The next revolution in laboratory medicine?
    Plebani, M
    [J]. CLINICA CHIMICA ACTA, 2005, 357 (02) : 113 - 122
  • [89] STRUCTURE AND BIOLOGICAL ROLE OF VITRONECTIN
    PREISSNER, KT
    [J]. ANNUAL REVIEW OF CELL BIOLOGY, 1991, 7 : 275 - 310
  • [90] Kinetics of fibrinopeptide release by thrombin as a function of CaCl2 concentration:: Different susceptibility of FPA and FPB and evidence for a fibrinogen lsoform-specific effect at physiological Ca2+ concentration
    Profumo, A
    Turci, M
    Damonte, G
    Ferri, F
    Magatti, D
    Cardinali, B
    Cuniberti, C
    Rocco, M
    [J]. BIOCHEMISTRY, 2003, 42 (42) : 12335 - 12348